Brief: Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. As Chief Medical Officer
23/11/2022 21:14
Nov 23 (Reuters) - Bright Minds Biosciences Inc
DRUG.CD :
* BRIGHT MINDS BIOSCIENCES APPOINTS DRUG DEVELOPMENT
EXECUTIVE
MARK A. SMITH M.D., PH.D. AS CHIEF MEDICAL OFFICER
Source text for Eikon: ID:nGNX5n6vf2
Further company coverage: DRUG.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bright Minds Biosciences
See all newsBright Minds Biosciences slips after increased $175 mln stock sale
Brief: Bright Minds Biosciences Announces Pricing Of Upsized US$175 Million Public Offering Of Common Stock At $90.00 Per Share
Bright Minds Biosciences falls after $100 mln equity offering launched
Brief: Bright Minds To Announce Topline Results For BMB-101 Phase 2 Trial In On Jan 6
Brief: Bright Minds Biosciences Files For Offering Of Up To 1.6 Million Common Shares By The Selling Securityholders